| Characteristics | Budesonide/formoterol 160/4.5 μg | |
| 1×2 | 2×2 | |
| Subjects n | 4008 | 4045 |
| Females % | 62 | 62 |
| Mean age (range) yrs | 48 (18–96) | 48 (18–90) |
| Mean FEV1 % pred | 85 | 85 |
| Mean reversibility % | 6 | 6 |
| Mean ICS dose at entry# μg·day−1 | 1046 | 1037 |
| LABA use % patients | 78 | 77 |
| Mean SABA use inhalations·day−1 | 1.5 | 1.5 |
| Mean patients with awakenings % | 42 | 43 |
| ACQ-5 >1.5 % of patients | 61 | 61 |
| BMI kg·m−2 | 27.4 | 27.4 |
1×2: one dose b.i.d.; 2×2: two doses b.i.d.; FEV1: forced expiratory volume in 1 s; % pred: % predicted; ICS: inhaled corticosteroids; LABA: long-acting β2-agonist; SABA: short-acting β2-agonist; ACQ-5: five-question Asthma Control Questionnaire; BMI: body mass index. #: expressed as beclomethasone dipropionate equivalent doses.